Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. PPBT
stocks logo

PPBT

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
--
--
-0.260
-80.98%
--
--
-0.340
+25.55%
Estimates Revision
The market is revising No Change the revenue expectations for Purple Biotech Ltd (PPBT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 28.61%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+28.61%
In Past 3 Month
Wall Street analysts forecast PPBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPBT is 34.00 USD with a low forecast of 34.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast PPBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPBT is 34.00 USD with a low forecast of 34.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.849
sliders
Low
34.00
Averages
34.00
High
34.00
Current: 0.849
sliders
Low
34.00
Averages
34.00
High
34.00
no data image
No Data

Valuation Metrics

The current forward P/E ratio for Purple Biotech Ltd (PPBT.O) is -0.50, compared to its 5-year average forward P/E of -6.46. For a more detailed relative valuation and DCF analysis to assess Purple Biotech Ltd 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.46
Current PE
-0.50
Overvalued PE
15.04
Undervalued PE
-27.95

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.68
Current PS
0.00
Overvalued PS
4.91
Undervalued PS
-1.56
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

PPBT News & Events

Events Timeline

(ET)
2025-11-14
08:07:49
Purple Biotech anticipates funding to last until the first half of 2027.
select
2025-11-14
08:07:12
Purple Biotech Announces Q3 Earnings Per Share of 29 Cents Compared to 39 Cents Last Year
select
2025-10-29 (ET)
2025-10-29
07:38:18
Purple Biotech Reaches Key Manufacturing Milestone for IM1240
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
10-30TipRanks
Three Penny Stocks to Keep an Eye on as of October 30, 2025

  • Penny Stocks to Watch: Cambium Networks, Purple Biotech, and Ernexa Therapeutics are highlighted as top penny stocks to monitor on October 30, 2025, based on their significant Dollar Volume and stock price movements.

  • Cambium Networks: The company experienced a Dollar Volume of $1.54 billion and a stock price increase of 377% following its integration with SpaceX's Starlink, enhancing its telecommunications solutions.

  • Purple Biotech: This clinical-stage biopharmaceutical company saw a Dollar Volume of $438.91 million and an 81% stock price surge after announcing a production milestone for its cancer treatment antibody, IM1240.

  • Ernexa Therapeutics: With a Dollar Volume of $375.25 million and a nearly 41% stock price rise, Ernexa is advancing its lead cell therapy for ovarian cancer through a partnership with Cellipont Bioservices.

[object Object]
Preview
9.5
10-30Benzinga
Alphabet Shares Rise Approximately 8%; Check Out 20 Stocks Making Moves in Premarket Trading

  • Alphabet Inc. Financial Results: Alphabet Inc. reported third-quarter revenue of $102.35 billion and earnings of $2.87 per share, both exceeding analyst expectations, leading to a 7.8% increase in share price during pre-market trading.

  • Pre-Market Stock Gainers: Several stocks saw significant gains in pre-market trading, including VCI Global Limited (+110%), Cambium Networks Corporation (+87.8%), and Guardant Health, Inc. (+22.3%), following positive financial announcements.

  • Pre-Market Stock Losers: Notable declines were observed in stocks such as CERo Therapeutics Holdings, which fell 75.8% due to a Nasdaq delisting determination, and Aditxt, which dropped 38.8% after announcing a reverse stock split.

  • Market Overview: The article highlights various stocks' performance in pre-market trading, showcasing both significant gainers and losers, reflecting the volatility and reactions to recent financial results and announcements.

[object Object]
Preview
4.5
10-29Benzinga
Dow Rises by 250 Points; Verizon Reports Mixed Results for Q3

  • U.S. Stock Market Performance: U.S. stocks rose this morning, with the Dow Jones gaining approximately 250 points, while the NASDAQ and S&P 500 also saw increases of 0.65% and 0.33%, respectively.

  • Sector Movements: Information technology stocks experienced a significant rise of 1.4%, whereas real estate stocks fell by 1.1% during trading.

  • Verizon's Financial Results: Verizon Communications reported mixed third-quarter results, with a 1.5% year-over-year revenue growth of $33.8 billion, falling short of analyst expectations, but exceeding EPS estimates.

  • Notable Stock Movements: Cambium Networks' shares surged 209% after a significant announcement, while Advent Technologies saw a 51% drop in its stock price following disappointing guidance.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Purple Biotech Ltd (PPBT) stock price today?

The current price of PPBT is 0.8488 USD — it has increased 8.16 % in the last trading day.

arrow icon

What is Purple Biotech Ltd (PPBT)'s business?

Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.

arrow icon

What is the price predicton of PPBT Stock?

Wall Street analysts forecast PPBT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PPBT is 34.00 USD with a low forecast of 34.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Purple Biotech Ltd (PPBT)'s revenue for the last quarter?

Purple Biotech Ltd revenue for the last quarter amounts to -1.37M USD, decreased -35.91 % YoY.

arrow icon

What is Purple Biotech Ltd (PPBT)'s earnings per share (EPS) for the last quarter?

Purple Biotech Ltd. EPS for the last quarter amounts to -1004000.00 USD, decreased -68.93 % YoY.

arrow icon

What changes have occurred in the market's expectations for Purple Biotech Ltd (PPBT)'s fundamentals?

The market is revising No Change the revenue expectations for Purple Biotech Ltd (PPBT) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 28.61%.
arrow icon

How many employees does Purple Biotech Ltd (PPBT). have?

Purple Biotech Ltd (PPBT) has 9 emplpoyees as of December 05 2025.

arrow icon

What is Purple Biotech Ltd (PPBT) market cap?

Today PPBT has the market capitalization of 7.65M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free